Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share Updates on Its PFN Program Pipeline at the Upcoming H.C Wainwright 23rd Annual Global Investor Conference

September 9, 2021 13:04:42
  • Tryp Therapeutics is set to present at the H.C Wainwright 23rd Annual Global Investor Conference scheduled for Sept. 13-15, 2021
  • Greg McKee, company chairman and CEO, will provide an overview of the business and its pipeline, including the Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program
  • Tryp’s presentation will be available on-demand from 7.00 a.m. EDT on Sept. 13
  • Through the PFN program, Tryp is focused on developing psychedelic compounds targeting diseases with high unmet medical needs, such as chronic pain conditions and eating disorders
As a company at the forefront of the psychedelic renaissance, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has differentiated itself by focusing on what most psychedelic drug development companies are not. Guided by an exceptional roster of scientific advisors and an experienced management team led by Tryp chairman and CEO Greg McKee, Tryp is developing psychedelic compounds targeting diseases with high unmet medical needs through its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program. The PFN program, which features TRP-8802 as the lead drug candidate and TRP-8803 as the proprietary formulation with a novel method of administration, targets chronic pain conditions, including fibromyalgia, phantom limb pain, complex regional pain syndrome and others, as well as eating disorders such as hypothalamic obesity, binge eating disorder and others. Tryp intends to proceed directly into Phase 2a human trials by leveraging existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803. To this end, it has partnered with leading academic institutions that have indication-specific expertise needed for the trials. Tryp has also entered into an agreement with a contract development and manufacturing organization (“CDMO”) for the research, development and GMP manufacturing services for synthetic psilocybin that will form the basis of the PFN program. It has further engaged another CDMO to develop the analytical methods and final formulations of its TRP-8802 and TRP-8803 products ( According to a recent press release, the company will present at the conference, with Greg McKee providing an overview of the business and its pipeline updates, including the PFN program. Tryp’s presentation will be available on-demand starting at 7:00 a.m. EDT on Sept. 13 ( Founded in 2019 and headquartered in San Diego, California, Tryp Therapeutics has made significant progress that positions it favorably in the promising psychedelic medical market. It is also similarly poised to leverage growth opportunities spanning multiple therapeutics markets, in line with its commitment to lead the next wave of psychedelic drug development beyond mental health. For more information, visit the company’s website at NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW) San Francisco, California 415.949.5050 Office PsychedelicNewsWire is part of the InvestorBrandNetwork.